155 related articles for article (PubMed ID: 18000164)
1. PACAP and its receptor VPAC1 regulate megakaryocyte maturation: therapeutic implications.
Freson K; Peeters K; De Vos R; Wittevrongel C; Thys C; Hoylaerts MF; Vermylen J; Van Geet C
Blood; 2008 Feb; 111(4):1885-93. PubMed ID: 18000164
[TBL] [Abstract][Full Text] [Related]
2. From patient to mouse to therapy: role of the neuropeptide pacap in platelet function and formation.
Freson K
Verh K Acad Geneeskd Belg; 2010; 72(5-6):239-51. PubMed ID: 21409952
[TBL] [Abstract][Full Text] [Related]
3. Thrombopoietic effect of VPAC1 inhibition during megakaryopoiesis.
Peeters K; Loyen S; Van Kerckhoven S; Stoffels K; Hoylaerts MF; Van Geet C; Freson K
Br J Haematol; 2010 Oct; 151(1):54-61. PubMed ID: 20735399
[TBL] [Abstract][Full Text] [Related]
4. The pituitary adenylate cyclase-activating polypeptide is a physiological inhibitor of platelet activation.
Freson K; Hashimoto H; Thys C; Wittevrongel C; Danloy S; Morita Y; Shintani N; Tomiyama Y; Vermylen J; Hoylaerts MF; Baba A; Van Geet C
J Clin Invest; 2004 Mar; 113(6):905-12. PubMed ID: 15067323
[TBL] [Abstract][Full Text] [Related]
5. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
6. The role of vasoactive intestinal peptide (VIP) in megakaryocyte proliferation.
Nam C; Case AJ; Hostager BS; O'Dorisio MS
J Mol Neurosci; 2009 Feb; 37(2):160-7. PubMed ID: 18663606
[TBL] [Abstract][Full Text] [Related]
7. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
8. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.
Mazzocchi G; Malendowicz LK; Neri G; Andreis PG; Ziolkowska A; Gottardo L; Nowak KW; Nussdorfer GG
Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629
[TBL] [Abstract][Full Text] [Related]
9. Backup Mechanisms Maintain PACAP/VIP-Induced Arterial Relaxations in Pituitary Adenylate Cyclase-Activating Polypeptide-Deficient Mice.
Ivic I; Fulop BD; Juhasz T; Reglodi D; Toth G; Hashimoto H; Tamas A; Koller A
J Vasc Res; 2017; 54(3):180-192. PubMed ID: 28490016
[TBL] [Abstract][Full Text] [Related]
10. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G
Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681
[TBL] [Abstract][Full Text] [Related]
11. cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells.
Nagata A; Tanaka T; Minezawa A; Poyurovsky M; Mayama T; Suzuki S; Hashimoto N; Yoshida T; Suyama K; Miyata A; Hosokawa H; Nakayama T; Tatsuno I
J Cell Physiol; 2009 Oct; 221(1):75-83. PubMed ID: 19496170
[TBL] [Abstract][Full Text] [Related]
12. Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide inhibit dendritic growth in cultured sympathetic neurons.
Drahushuk K; Connell TD; Higgins D
J Neurosci; 2002 Aug; 22(15):6560-9. PubMed ID: 12151535
[TBL] [Abstract][Full Text] [Related]
13. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression.
Delgado M; Sun W; Leceta J; Ganea D
J Immunol; 1999 Oct; 163(8):4213-23. PubMed ID: 10510358
[TBL] [Abstract][Full Text] [Related]
14. High-Fat Diet Augments VPAC1 Receptor-Mediated PACAP Action on the Liver, Inducing LAR Expression and Insulin Resistance.
Nakata M; Zhang B; Yang Y; Okada T; Shintani N; Hashimoto H; Yada T
J Diabetes Res; 2016; 2016():9321395. PubMed ID: 28044141
[TBL] [Abstract][Full Text] [Related]
15. PAC1 receptors mediate pituitary adenylate cyclase-activating polypeptide- and progesterone-facilitated receptivity in female rats.
Apostolakis EM; Riherd DN; O'Malley BW
Mol Endocrinol; 2005 Nov; 19(11):2798-811. PubMed ID: 15976009
[TBL] [Abstract][Full Text] [Related]
16. Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) impairs the regulation of apoptosis in megakaryocytes by activating NF-κB: a proteomic study.
Di Michele M; Peeters K; Loyen S; Thys C; Waelkens E; Overbergh L; Hoylaerts M; Van Geet C; Freson K
Mol Cell Proteomics; 2012 Jan; 11(1):M111.007625. PubMed ID: 21972247
[TBL] [Abstract][Full Text] [Related]
17. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
18. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA
Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463
[TBL] [Abstract][Full Text] [Related]
19. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
[TBL] [Abstract][Full Text] [Related]
20. [Pituitary adenylate cyclase-activating polypeptide].
Gonzalez BJ; Basille M; Vaudry D; Fournier A; Vaudry H
Ann Endocrinol (Paris); 1998 Dec; 59(5):364-405. PubMed ID: 9949891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
